S100A9 and pancreatic ductal adenocarcinoma: In pancreatic diseases, previous studies have indicated that pancreatic ductal adenocarcinoma (PDAC) patients with elevated levels of S100A9 in the ductal fluid have a notably worse prognosis 20 and the plasma level of S100A9 is also significantly increased in AP mice and patients 21,22.